Education
About Us
Working with TipRanks
Follow Us
MDxHealth (MDXH)
NASDAQ:MDXH
MDXH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.35 - $3.50
Previous CloseN/A
Volume27.23K
Average Volume (3M)75.19K
Market Cap
$136.12M
Enterprise Value$88.59M
Total Cash (Recent Filing)$65.67M
Total Debt (Recent Filing)$83.98M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Nov 12, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding49,497,334
10 Day Avg. Volume112,470
30 Day Avg. Volume75,188
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)7.77
Price to Sales (P/S)1.28
P/FCF Ratio-5.85
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue0.94
Enterprise Value/Gross Profit1.51
Enterprise Value/Ebitda-6.60
Forecast
1Y Price Target
$6.00Price Target Upside122.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Acquisition StrategyThe agreement for MDx to acquire the Exosome Diagnostics business from Bio-Techne is expected to result in shares moving higher over the near and intermediate term.
Financial PerformanceMDxHealth announced several positive updates, including preliminary second-quarter revenue results that met expectations and reaching AEBITDA positivity in the second quarter.
Market ValuationWith shares trading at under 1 times NTM revenue, the company’s growth outlook and commercial infrastructure are significantly undervalued, suggesting room for multiple expansion.
Bears Say
Price Target AdjustmentThe price target was adjusted from $7.00 to $5.00, indicating a more conservative outlook.
MDxHealth News
MDXH FAQ
What was MDxHealth’s price range in the past 12 months?
MDxHealth lowest stock price was $1.35 and its highest was $3.50 in the past 12 months.
What is MDxHealth’s market cap?
MDxHealth’s market cap is $136.12M.
When is MDxHealth’s upcoming earnings report date?
MDxHealth’s upcoming earnings report date is Nov 12, 2025 which is in 96 days.
How were MDxHealth’s earnings last quarter?
MDxHealth released its earnings results on Aug 05, 2025. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.123 by -$0.027.
Is MDxHealth overvalued?
According to Wall Street analysts MDxHealth’s price is currently Undervalued.
Does MDxHealth pay dividends?
MDxHealth does not currently pay dividends.
What is MDxHealth’s EPS estimate?
MDxHealth’s EPS estimate is -0.11.
How many shares outstanding does MDxHealth have?
MDxHealth has 49,497,334 shares outstanding.
What happened to MDxHealth’s price movement after its last earnings report?
MDxHealth reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.123. Following the earnings report the stock price went up 10.442%.
Which hedge fund is a major shareholder of MDxHealth?
Currently, no hedge funds are holding shares in MDXH
MDxHealth Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.00 (122.22% Upside)
$6.00 (122.22% Upside)
Crowd Wisdom
Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.29%
12-Months-Change
Fundamentals
Return on Equity
-1552.23%
Trailing 12-Months
Asset Growth
43.61%
Trailing 12-Months
Company Description
MDxHealth
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
MDXH Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance by MDxHealth, with consistent revenue growth driven by tissue-based tests and improved gross margins. However, challenges remain with increased net loss and the impact of a significant earn-out payment. Overall, the company's strategic positioning and future outlook appear positive, but financial losses present ongoing challenges.View all MDXH earnings summariesMDXH Stock 12 Month Forecast
Average Price Target
$6.00
▲(122.22% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.09% Mutual Funds
0.07% Other Institutional Investors
99.67% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---